Qiagen to ally with Clovis Oncology on lung cancer companion Dx; T2 Biosystems broadens diagnostic detection patents

> Qiagen ($QGEN) will work with Clovis Oncology ($CLVS) on a companion diagnostic that would identify patients who could benefit from an EGFR-targeting lung cancer treatment. Story

> T2 Biosystems, a 2012 FierceMedicalDevices Fierce 15 company, has obtained two additional patents broadening protection for signature diagnostic detection technology behind its T2Candida blood test. Item

> An experimental blood test developed by Integrated Diagnostics has shown promise in detecting early lung cancer well beyond the capacity of scans and invasive biopsies, researchers have concluded. Story

> A molecular diagnostics prototype platform developed by Biocartis in Belgium can detect BRAF mutations in melanoma and other cancer types faster and more accurately than current technology, according to a new study. Item

> Miraca Life Sciences, a company focused on anatomic pathology services, has snatched up PLUS Diagnostics from Water Street Healthcare Partners for an undisclosed price. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.